Immuron Limited is a biopharmaceutical company that researches and develops polyclonal antibodies. The company operates in two segments and focuses on marketing Travelan and Protectyn. It is also conducting clinical trials for its products to reduce the risk of contracting travelers' diarrhea, treat recurrent clostridium difficile infection, and develop therapeutics targeting Campylobacter and ETEC infections.